FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers direct access to trial results as they accumulate, not after a completed package arrives.
It’s a shift from a review system built around finished submissions. FDA has traditionally sat on the receiving end of a sponsor’s data package. This program puts reviewers inside the data stream while the trial runs.
If FDA can track trial data live, it can flag issues mid-study, before a sponsor locks and files. That could compress post-submission back-and-forth. It could also mean companies get earlier warnings on trials heading toward failure, before they’ve committed further resources.
The program is a pilot, which means feasibility hasn’t been proven at scale. What data types are covered, how many trials participate, and what authority FDA reviewers have to act on real-time data mid-trial remain open questions. Pilot results will likely shape whether this becomes standard practice.
For sponsors, the core question is whether real-time FDA visibility is an advantage or an exposure. Either way, the traditional boundary between an active trial and its regulator just changed.
— Sarah Chen